The success rate of radium 223 therapy varies depending on several factors, including the extent of bone metastases and the patient's overall health. Clinical studies have demonstrated a median survival benefit of approximately three to six months in patients with CRPC. Additionally, significant improvements in quality of life and pain management have been reported.
